There is no FDA-approved oral tirzepatide. Compounded sublingual and oral dissolvable tirzepatide exists, but bioavailability data for these formulations is limited and not comparable to the injectable trial evidence. The approved oral options are semaglutide tablets and orforglipron.
What exists and what does not
Injectable tirzepatide is the only formulation with Phase 3 evidence. Some compounding pharmacies prepare sublingual drops or oral dissolvable tablets containing tirzepatide. Peptides are poorly absorbed orally without absorption enhancers, which is precisely why oral semaglutide required a specific formulation technology and a fasting protocol.
This does not mean compounded oral tirzepatide does nothing. It means nobody has published the pharmacokinetic data that would let you convert a sublingual dose to an injectable equivalent. Treat efficacy claims for these products with more skepticism than injectable claims.
The approved needle-free routes
Oral semaglutide tablets are approved and effective, with a strict fasting requirement. Orforglipron (Foundayo), approved 1 April 2026, is a small-molecule oral GLP-1 with no food or water restriction and roughly 12.4% mean weight loss at the top dose in ATTAIN-1 — below injectable tirzepatide but the most convenient option on the market.
If needles are the barrier
Most people find the injection far less unpleasant than they expected — the needle is very short and very fine. Before you trade a 20% drug for a 12% drug on needle anxiety alone, it is worth trying once with guidance from your prescriber's team.
Common questions
How much does tirzepatide cost per month without insurance?
Compounded tirzepatide from licensed US telehealth programs runs roughly $99 to $299 per month depending on the provider and whether the price is flat or scales with your dose. Brand-name Zepbound through LillyDirect self-pay runs about $299 to $449 per month depending on strength. Retail Zepbound without any program is around $1,089.
Is compounded tirzepatide the same as Zepbound?
The active ingredient is the same molecule. Zepbound is FDA-approved, manufactured by Eli Lilly and reviewed by FDA for safety, effectiveness and quality. Compounded tirzepatide is prepared by a state-licensed pharmacy for an individual patient and is not FDA-approved or FDA-reviewed. The pharmacology is identical; the quality assurance structure is not.
How much weight will I lose on tirzepatide?
In SURMOUNT-1, mean 72-week weight loss was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, versus 3.1% on placebo. If you have type 2 diabetes, expect roughly two-thirds of those figures based on SURMOUNT-2. Real-world averages run lower than trial averages, mostly because people stop early.
Is tirzepatide better than semaglutide?
For weight loss, yes, on the available randomized evidence. SURMOUNT-5 compared them head-to-head over 72 weeks and found 20.2% mean loss on tirzepatide versus 13.7% on semaglutide. Semaglutide retains a stronger cardiovascular outcomes label from the SELECT trial and is cheaper in compounded form.
People also ask about oral tirzepatide
What is oral tirzepatide?
Oral tirzepatide is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does oral tirzepatide apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does oral tirzepatide cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is oral tirzepatide FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.